The StayGreen Oil Introduces Its Revolutionary Used Oil Marketplace

The Web-Based Solution Greatly Increases Efficiency, Reduces Cycle Time, and Provides a Centralized Database for Recording Used Oil and Used Cooking Oil Collection Data in the US and Abroad.

LAKELAND, Florida  (Sharewellnewswire.com) September 13, 2012 – StayGreen Oil, LLC, a global provider of used lubricant and used cooking oil technology solutions announced today it has launched its StayGreen Oil Marketplace (www.staygreenoil.com). The StayGreen Marketplace is designed as cloud based service intended for use by Buyers and Sellers of used lubricants and cooking oils to enable them to acquire the best vendor and price across broad geographic service regions.

"The most exciting part of our solution is the fact that the StayGreen Marketplace is a completely innovative approach to an industry that is ripe for automation and standardization of normal business practices. Our platform not only fosters new relationships between buyers and sellers of used lubricants and cooking oils, it also allows parties on both sides of the market to track and manage needs across their enterprise, " said Brian Davis, co-founder of StayGreen Oil. 

The StayGreen marketplace is free for Buyers and Sellers to register and interact through public auctions or via private requests for proposal. Currently deployed in the United States, the company has plans for expanding the platform to international markets. Michael Griffith, co-founder says, "There currently exists a growing global demand for re-refined basestocks derived from used engine oils and an increased call for used cooking oils required for biodiesel production. StayGreen Oil is the only system of its kind and will revolutionize the way the market interacts to fill these needs.”

About StayGreen Oil, LLC:

Based in Florida, StayGreen Oil is an aggressive growth business designed to drive value for sellers and buyers of used lubricants and cooking oils. For information please visit www.staygreenoil.com or call 866.725.4053.

Contact Info:
866.725.4053
http://www.staygreenoil.com
StayGreen Oil

Source: The StayGreen Oil Introduces Its Revolutionary Used Oil Marketplace (SharewellNewswire.com)

Edmond Masjedi, Creates Marketing Company With Unique Approach To The Marketplace

Los Angeles, CA  (Sharewellnewswire.com) September 13, 2012 –  Successful businessman and Financial Expert Edmond Masjedi, is the creator of a marketing company to have one of the most unique and intriguing approaches in the marketplace.  

Edmond Masjedi has been able to attract the attention of consumers for all kinds of brands through his unique marketing approach and campaigns.  Consumers are drawn to interesting yet informative marketing campaigns that show them how to identify with the product. 

Most of the advertisements used in Edmond Masjedi’s marketing approach are interactive ads on the products they represent with the audience, and are in the form of 3D.    Using 3D in advertisements is a very unique and interesting approach to get the message across.

Edmond Masjedi’s style to marketing approach ensures that most of the ads are also covered by media and press.  The key to drawing attention to your product is by also drawing in as much media coverage as possible.

Through these unique ads and his marketing approach, Edmond Masjedi is issuing a way for himself in the marketing field.

About Edmond Masjedi Edmond Masjedi is has had a long career that has been filled with numerous successes and achievements. Over the years he has started many companies in varied lines of businesses. Under the leadership and guidance of Edmond Masjedi, all of these companies have been a great success and have generated huge revenues. 

Visit www.edmondmasjedi.com for more information about Edmond Masjedi’s marketing approaches and business philosophies.

###

Contact Info:
eddiemasjedi@aol.com
http://www.edmondmasjedi.com
Edmond Masjedi
5021 Adams Place
Suite 136, Plano TX 08807

 

Source: Edmond Masjedi, Creates Marketing Company With Unique Approach To The Marketplace (SharewellNewswire.com)

The WaterAid Salutes the 2012 UNICEF ‘Levels & Trends in Child Mortality’ Report

New York (Sharewellnewswire.com) September 13, 2012 – A new report released today by UNICEF, the United Nations Children’s Fund, shows that the number of under-five deaths worldwide has declined from nearly 12 million in 1990 to 6.9 million in 2011. ‘Levels & Trends in Child Mortality’ is based on estimates developed by the UN Inter-agency Group for Child Mortality Estimation and highlights enormous global progress in ending preventable child deaths worldwide. Yet, much more is required to bring these numbers to zero, chief among which is ensuring universal access to safe drinking water, improved sanitation, and hygiene promotion among the world’s poorest people and communities.

Dr. David Winder, CEO of WaterAid in America, speaking about the new UNICEF ‘Levels & Trends in Child Mortality’ Report stated:

"There is ample evidence to support the critical role of safe drinking water, sanitation and hygiene (WASH) in helping to save seven million young children who are currently dying every year from entirely preventable causes. In fact, WASH is closely linked to three leading killers of children—pneumonia, diarrheal diseases and malaria—and to under-nutrition, to which more than one-third of under-five deaths is attributed. Without improved sanitation, hygiene and water resource management, we will not make sufficient headway in providing all children with the health and opportunities they deserve.

This is one of many reasons that WaterAid is a proud partner of A Promise Renewed, a global partnership led by UNICEF and the Governments of the United States, Ethiopia and India, which aims to align the global community around a commitment to end preventable child deaths through a series of high-impact interventions, including WASH. Yet, this critically important effort will not succeed without significantly increased resources from all stakeholders and improved targeting of funds to ensure the poorest and most vulnerable are being reached.”

The report shows that 11% of childhood deaths (759,000 per year / 2,079 per day) are attributable to diarrheal diseases, of which 88% (according to the WHO) can be directly attributed to a lack of clean water, safe sanitation and hygiene promotion. Additionally, a full 50% of global malnutrition is attributed to lack of access to high quality safe drinking water, sanitation and hygiene services, showing how critical WASH is as a foundation to health.

The latest access figures (for 2010) show that 2.5 billion people (around 1 in 3 of the world’s population) still lack access to sanitation, while 783 million people (around 1 in 10 of the world’s population) still lack access to clean drinking water.

In order to redress these gaps in basic dignity and human rights and contribute to ending preventable childhood deaths, WaterAid calls on the United States Congress to provide $400 million for safe drinking water, sanitation and hygiene, as approved for Fiscal Year 2013 by the Senate Appropriations Committee; and to urgently pass the Senator Paul Simon Water for the World Act (H.R. 3658 and S. 641) in order to ensure that US agencies are focused on spending existing resources most effectively and increasing transparency in how they prioritize WASH interventions around the world, without spending any new money.

###

For further information or interview requests, please contact Susannah Gold sgold@wateraidamerica.org or +1 917 207 5375

• Embargoed copies of the new UNICEF ‘Levels & Trends in Child Mortality’ Report are available from the UNICEF media team, or via email from WaterAid.
  
• Details as to the levels of water and sanitation access across the globe can be accessed fromwww.wssinfo.org
• WaterAid’s vision is of a world where everyone has access to safe water and sanitation. The international organisation works in 27 countries across Africa, Asia, Central America and the Pacific region to transform lives by improving access to safe water, hygiene and sanitation in some of the world’s poorest communities. Over the past 30 years, WaterAid has reached 15.9 million people with safe water and, since 2004, 11 million people with sanitation. For more information, visit www.wateraidamerica.org, follow @wateraid on Twitter or visit us on Facebook at http://www.facebook.com/ WaterAidAmerica.
• Further information on A Promise Renewed and evidence-based analysis of the highest-impact interventions to prevent under-five mortality rates is available at www.APromiseRenewed.org. A list of signatories to a non- governmental organization pledge to support and advance the objectives and approaches of A Promise Renewed are also available, in addition to a government pledge that has been signed by almost half of the world’s governments.
• The Senator Paul Simon Water for the World Act (H.R 3658 and S. 641) is a bipartisan initiative led by Congressmen Judge Ted Poe (R-TX) and Earl Blumenauer (D-OR) and Senators Bob Corker (R-TN) and Richard Durbin (D-IL). Its objectives are to improve the efficiency of existing US investments in safe drinking water, sanitation and hygiene; to increase transparency of investments and analysis of greatest impact; to enhance coordination across US foreign policy objectives; and to build US and global capacity to implement best-practice WASH programs—all without increasing the funds required.
• 783 million people in the world do not have access to safe water. This is around 1 in 10 people worldwide.
• 2.5 billion people in the world do not have access to adequate sanitation. This is around 1 in 3 people worldwide.
• An estimated 5-6% of Gross Domestic Product in countries of sub-Saharan Africa and South Asia is lost each year due to lack of access to WASH.
• For every $1 invested in water and sanitation, $8 is returned in increased economic productivity and reduced health care costs.
• Just $25 can enable one person to access safe water, improved hygiene and sanitation.

Source: The WaterAid Salutes the 2012 UNICEF ‘Levels & Trends in Child Mortality’ Report(Sharewell Newswire.com)

The MEDICAL CARE TECHNOLOGIES INC. ANNOUNCES $1,500,000 MEMORANDUM OF UNDERSTANDING TO SECURE EQUIPMENT FOR HEALTH CENTER OPERATIONS

Partnership Will Equip Kids Health Centers with State-of-the-Art Medical Equipment

BEIJING, CHINA (Sharewellnewswire.com) September 13, 2012 – Medical Care Technologies Inc. (OTCBB: MDCE), a growing American company providing children’s healthcare services and Western healthcare products distribution in China, today announced that it has signed a memorandum of understanding (MOU) with Dragon Link Group Ltd. (“Dragon Link”) establishing the framework for a strategic investment through which Dragon Link would invest over $1.5 million for medical equipment and clinical tools.

Dragon Link is a Hong Kong private company and its proposed investment in Medical Care Technologies Inc. is intended to create the capital structure necessary for the Company to outfit its first health center operation in Shenzhen and, to expand its operations throughout Guangdong Province.

Under the proposed terms of the strategic agreement outlined in the MOU, Dragon Link would provide the Company with up to $1.5 million in equipment financing, with an initial cash outlay of $400,000 to outfit the Shenzhen Children’s Health and Wellness Center with German- manufactured health and dental equipment. This $1,500,000 proposed investment into Medical Care Technologies comes without having to add any new shares into the Company's current share structure.

"A substantial capital investment from Dragon Link would not only secure our equipment financing for Shenzhen, but it would also secure equipment funding for our other planned health center locations,” said Ning Wu, CEO of Medical Care Technologies Inc. “In addition, this agreement would align us with a large, successful global brand in the medical equipment industry," she added.

"This MOU is the first step toward a longer term agreement through which we plan to build on the foundation of Medical Care Technologies Inc.’s Shenzhen operation," said Fielding Sy, President of Dragon Link. “We believe this partnership will create long-term value to the customers, investors and other stakeholders of both companies," he further stated.

While the MOU is non-binding and the execution of definitive documentation is subject to negotiation, both companies are currently negotiating and intend to close the full transaction by the end of the month.

About Medical Care Technologies Inc.
Medical Care Technologies Inc. is traded under the symbol MDCE on the OTCBB and is headquartered in Beijing, China. MDCE, through joint ventures or Chinese subsidiaries, develops a network of children’s health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class and upper class Chinese families. Specializing in the care of children between the ages of 3 to 16, MDCE’s role is to enhance the overall well-being of the family and community and to expand its pediatric services to include preventative health and wellness education. MDCE, through its children’s health facilities, will also distribute a diverse range of industry-leading pharmaceutical and nutraceutical product lines. MDCE’s main mission is simple – to become a healthcare service provider leader in children’s health. Information on the Company can be found at www.sec.gov and the Company’s website atwww.medicaretechinc.com.

Safe Harbor Statement
All statements contained in this press release, other than statements of historical fact, are forward-looking statements, including those regarding: MDCE’s products, services, capabilities, performance, opportunities, development and business outlook, guidance on our future financial results and other projections or measures of our future performance; the amount and timing of the benefits expected from strategic initiatives and acquisitions or from deployment of new or updated technologies, products, services or applications; and other potential sources of additional revenue. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements. These risks and uncertainties include those relating to: lack of operating history, transitioning from a development company to an operating company, difficulties in distinguishing MDCE’s products and services, ability to deploy MDCE’s services and products, market acceptance of our products and services; operational difficulties relating to combining acquired companies and businesses; our ability to form and maintain mutually beneficial relationships with customers and strategic partners; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and healthcare and pharmaceutical industries, and our ability to attract and retain qualified personnel. Other risks and uncertainties may include, but are not limited to: lack of or delay in market acceptance and fluctuations in customer demand, dependence on a limited number of significant customers, reliance on third party vendors and strategic partners, ability to meet future capital requirements on acceptable terms, continuing uncertainty in the global economy, and compliance with federal and state regulatory requirement. Further information about these matters can be found in our Securities and Exchange Commission filings. We expressly disclaim any intent or obligation to update these forward-looking statements.

Contact Info:
Ms. Candy Wang, Mr. Peter Verner
(852) 8122-9660
Email: contact@medicaretechinc.com, p.verner@medicaretechinc.com
http://www.medicaretechinc.com

Source: The MEDICAL CARE TECHNOLOGIES INC. ANNOUNCES $1,500,000 MEMORANDUM OF UNDERSTANDING TO SECURE EQUIPMENT FOR HEALTH CENTER OPERATIONS (SharewellNewswire.com)

NORTHWEST BIO RECEIVES REGULATORY APPROVAL TO PROCEED WITH ITS PHASE III TRIAL IN THE UK

NW Bio Now in Phase III Clinical Trial for Brain Cancer in Both the U.S. and Europe

BETHESDA, MD (Sharewellnewswire.com) September 12, 2012 -- Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) announced today that it has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom (the U.K.’s “FDA”), for the Company’s 300- patient Phase III clinical trial of DCVax®-L immune therapy for Glioblastoma multiforme brain cancer (GBM) to proceed in the U.K.

This Phase III clinical trial is already under way in the U.S., at 41 sites across the country. NW Bio is now expanding this Phase III trial to make it an international trial, by including clinical trial sites in Europe. This international approach can potentially save years of time in clinical trials, compared with conducting trials in the U.S. and Europe separately.

NW Bio’s submission of the Phase III trial application to the U.K.’s MHRA, as well as the MHRA’s acceptance of the trial’s designation as a Phase III trial and rapid approval of the trial, mark the culmination of two years of preparatory work and foundation-building in the U.K.

NW Bio has already obtained Ethics Committee approval for this trial on a centralized basis from the National Research Ethics Committee in the U.K. Such Ethics Committee approval is equivalent to Institutional Review Board (IRB) approvals in the U.S. This centralized approval from the National Research Ethics Committee applies throughout the U.K., eliminating the need to obtain Ethics Committee (IRB) approvals at each clinical trial site (which typically takes months at each site in the U.S.).

The U.K. has one of the largest populations in Europe (63 million), nearly equal to that of France (65 million), and exceeded only by Germany (82 million). Under the U.K.’s National Health System, medical centers cover certain designated territories, and medical specialties tend to be clustered – which enables heightened efficiencies in clinical trials for diseases such as brain cancer.

“We are excited and very grateful to the MHRA for its rapid approval, allowing our GBM brain cancer trial to proceed as a Phase III trial in the U.K. as an expansion of the ongoing Phase III trial in the U.S.” commented Linda Powers, CEO of NW Bio. “There is an urgent medical need for better treatment options for GBM, the most lethal form of brain cancer. We appreciate the opportunity to efficiently include the U.K. in our ongoing Phase III trial, so that we can bring the DCVax®-L immune therapy to patients in the U.K. as well as the U.S.”

For further information about the Company and its programs, please visit the Company’s website atwww.nwbio.com.

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis, in both the United States and Europe. The Company has a broad platform technology for DCVax® dendritic cell-based vaccines. The Company’s lead program is a 300-patient Phase III trial in newly diagnosed Glioblastoma multiforme (GBM). GBM is the most aggressive and lethal brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I/II trials in multiple other cancers. The Company has also conducted a Phase I/II trial with DCVax® for metastatic ovarian cancer.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax® and future clinical trials, are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “believe,” “intend,” "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company’s ability to raise additional capital, risks related to the Company’s ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company’s products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company’s results, is included in its Securities and Exchange Commission (“SEC”) filings. Finally, there may be other factors not mentioned above or included in the Company’s SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

Contact Info:
Les Goldman , Jennifer Zimmons
202-841-7909
lgoldman@nwbio.com, jzimmons@cgc-us.com
212-209-7360
Northwest Biotherapeutics, Inc.
4800 Montgomery Lane, Suite 800
Bethesda, MD 20814

Source:  NORTHWEST BIO RECEIVES REGULATORY APPROVAL TO PROCEED WITH ITS PHASE III TRIAL IN THE UK(SharewellNewswire.com)

Nation’s Best Christian Colleges Announced in 22nd Annual National College Survey

Rome, GA (Sharewellnewswire.com) September 12, 2012 – The results of the 22nd Annual National College Survey of 1,447 colleges and universities have been announced. With the cost of some of America’s best colleges approaching $60,000 per year, this year’s list of America's Best Christian Colleges ®identifies exceptional opportunities.

The survey was conducted by Institutional Research & Evaluation, Inc., an independent educational research and consulting organization based in Rome, Georgia. "This is the sixteenth year we have identified the best Christian colleges. Ratings are based exclusively on facts,” stated Lewis T. Lindsey, Jr., President of the consulting firm.

Among the criteria for America's Best Christian Colleges ®, institutions must have a freshman class with an academic profile equal to or above the national average for freshmen entering Christian colleges and universities. The survey results showed that the average entering Christian college freshman had a high school grade point average of 3.31 on a 4.0 scale, an average SAT score of 1069 in critical reading and math, and the average ACT score was 22.

According to Lindsey, “We do not use data that can skew results. All institutions, large and small, can be evaluated on the basis of the academic ability of their most recent entering freshman class. This year 279 Christian colleges responded to the survey with eighty-nine meeting the requirements."

The 2012 survey revealed that Pennsylvania offers the most qualifying institutions with nine schools, while 29 states had at least one institution that qualified. Eighteen denominations are represented with Baptist institutions leading the list with 23 schools, followed by Catholic schools with 18, and non-denominational with 15.

"America’s best college buys include outstanding Christian colleges offering high quality educational environments,” states Lindsey. “Higher education can be expensive, but a high quality Christian education can be very affordable. Prospective students and their parents should make every effort to select the best college or university for their money."

A link to the complete report of America's Best Christian Colleges ® can be found at the website:www.100bestcollegebuys.com.

Queries or interviews are welcome.

Contact Info:
Lewis T. Lindsey, Jr.
ire@comcast.net
706.295.5871, ext. #4
http://www.100bestcollegebuys.com

Source:  Nation’s Best Christian Colleges Announced in 22nd Annual National College Survey(SharewellNewswire.com)

“SAWDUST” 3D TV Pilot Casts the Movie Icon Mamie Van Doren in a Leading Role

LOS ANGELES (Sharewellnewswire.com) September 12, 2012 - Sawdust Productions has signed cinema icon Mamie Van Doren to play a lead role in "SAWDUST" the first 3D television series to be shot in 3D and 2D. The pilot for the half-hour episodic drama, set within the world of a depression-era, 1930s circus, is being funded through the crowd-sourcing platform Kickstarter.


Ms. Van Doren will play ‘Victoria,’ the glamorous but tough-minded owner of a 1930’s Depression-era circus struggling to keep the show on the road. This marks Mamie’s first acting role since her cameo appearance in the 2002 Dewey Nicks film, “Slackers.” She is best known for starring roles in a number of influential films from the 1950s and 60s including “High School Confidential,” “Untamed Youth” and “Teacher’s Pet,” opposite Clarke Gable and Doris Day. As a singer, she recently appeared in a guest performance with Pink Martini at the Greek Theater.

“We’re extremely fortunate to have our ‘Victoria’ being played by Mamie Van Doren,” said “SAWDUST” Executive Producer Wayne Schoenfeld. “This will be exciting for Mamie’s legion of fans around the world as well as an opportunity to expose her talent to new audiences.
“I couldn’t be more thrilled to be participating in a cutting edge project like “SAWDUST,” said Miss Van Doren. “I always wanted to run away and join the circus and playing the role of ‘Victoria’ is my chance to do that. It’s the opportunity of a lifetime and I can’t wait for audiences to experience this wonderful series in 3D.” Donors to the “SAWDUST” Kickstarter campaign will receive a personalized gift from Mamie Van Doren in addition to other premium items.

Co-Executive Producer Anthony Coogan, a 3D technology expert and son of legendary movie and TV star Jackie Coogan (“The Kid” with Charlie Chaplin and Uncle Fester in “The Addams Family”) noted that his father co-starred with Ms. Van Doren in four movies. “This project links Hollywood’s Golden Era with its bright future,” said Coogan. “Mamie Van Doren in 3D is going to be a visual delight.”

“SAWDUST” producers are currently casting for the series and will be making announcements regarding filled cast and crew positions in the coming weeks.

ABOUT MAMIE VAN DOREN
Mamie Van Doren’s “bad girl,” roles in the 50’s and 60’s signaled the advent of the sexual revolution. Equipped with a halo of platinum hair and a bullet bra, Mamie power housed her way through more than 40 motion pictures, including the cult classics “Untamed Youth” (1957), (in which she was the first actress to sing rock and roll on screen), “High School Confidential!” (1958), “Guns, Girls and Gangsters” (1959) and “Sex Kittens Go To College” (1960). Her on- screen leading men included Clark Gable, Donald O'Conner, Mickey Rooney, Jeff Chandler, Jean Pierre Aumont, and Tony Curtis.

The only surviving member of the trio of Blonde Bombshells known in the 50s as “The Three M’s” – Mamie, Monroe and Mansfield – Mamie Van Doren carved a special niche for herself in cinema history; one that was very different from her peers. Instead of Marilyn’s vulnerability, or Jayne Mansfield’s comedic caricature, Mamie’s heroines were tough and street wise, yet always with a heart of gold—a dynamic combination of Jean Harlow, Mae West and Lana Turner. Mamie has also appeared in films in Italy, Spain, Germany, and Argentina.

ABOUT SAWDUST PRODUCTIONS
Sawdust Productions, based in Los Angeles, Calif., is a creative collaboration between New Democracy Productions and Stereomedia 3D HD Digital in the United States and P2P Productions in Canada. Principals include award-winning filmmaker and photographer Wayne Schoenfeld, Producer, photographer and creator of Icons and Iconoclasts, the widely heralded book that recreated a 1930s-era circus; Stereoscopic Director Anthony Coogan; and Nadia Duguay of EXEKO, an international non-profit organization and winner of the 2009 Medal of Peace.
Editors Note: Photos of Mamie Van Doren are available by request. To review “Sawdust” photographs and promotional video, please visit www.wayneschoenfeld.com.

Additional information :
Sawdust Website

Contact Info:
John Grimshaw, Producer
760-420-0151
john@admanium.com
Sawdust Productions

Source: “SAWDUST” 3D TV Pilot Casts the Movie Icon Mamie Van Doren in a Leading Role(SharewllNewswire.com)